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Abstract 1687
Background: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder resulting from the
t(9;22)(q34;q11) balanced reciprocal translocation within a pluripotent stem cell (SC). The resulting
Philadelphia (Ph) chromosome produces BCR-ABL1 fusion gene coding for a deregulated Abl tyrosine-
kinase with constitutive and tumorigenic activity. The first line therapy of CML is imatinib mesylate, which
targets Bcr-Abl protein, inhibiting proliferation pathways. Complete cytogenetic response can be achieved in
95% of patients treated in the early chronic phase (CP)1. Molecular monitoring of minimal residual disease is
crucial to detect poor responses to imatinib and optimizing treatment with second generation tyrosine-kinase
inhibitors or allogeneic stem cell transplantation. Residual leukemia is assessed by a quantitative manner
evaluating levels of BCR-ABL1 transcripts by real-time reverse transcriptase PCR (qRT-PCR). Although
qRT-PCR detects mRNA levels in a very sensitive manner, the negative result is difficult to interpret,
because undetectable levels of chimeric transcript can reflect either an effective elimination of leukemia
cells, or the presence of a quiescent leukemia SC transcriptionally silent.
Methods: We developed a novel highly sensitive method to identify quiescent leukemic cells through
quantitative real-time PCR (Q-PCR) targeting the genomic breakpoint sequence1. In CML each patient
shows a unique genomic fusion sequence1, that need to be characterized in order to design a specific
genomic assay. We selected 14 patients with CML diagnosed in the early CP. We identified junctions
sequences by long-range PCR2. We carried out Q-PCR assay using common primer forward and probe in
BCR, and 2 different primers reverse, in ABL or BCR, used as control1. The percentage of leukemic cells
(LCs) was calculated using the derivation of the Ct formula1: LC= [100*(2/2 Ct+1)]/n], where Ct is the
difference between amplification cycles of BCR-ABL1 and BCR reactions, and n is the number of
experimental replicates. We tested the sensitivity and the efficiency of the method on K562 cell line.
According to the human C value, K562 were diluted in normal commercial genomic DNA until 10–4
dilutions. Eight CML patients in early CP were the object of this study. A patient specific Q-PCR assay was
performed on DNA obtained at diagnosis and subsequently applied to monitor minimal residual disease
during Imatinib treatment for up to 8 years, for a total of 61 samples. In parallel the same peripheral blood
samples were tested by standard qRT-PCR, and the percentage of residual disease (international scale)
measured by mRNA was compared with DNA analysis.
Results: Positive levels of mRNA were obtained in 79% of samples analyzed by qRT-PCR,while we
detected Ph-positive cells in 92% of samples. In all positive samples for chimeric transcript we measured
positive levels of corresponding genomic DNA, confirming the sensitivity of the Q-PCR method. In 13% of
samples, with undetectable levels of mRNA, we observed the persistence of quiescent leukemic cells,
transcriptionally silent like shown by patient 2 in figure 1. This could probably indicate the presence of
pluripotent LSCs or progenitor cells, that does not respond to imatinib treatment. Finally undetectable levels
of mRNA were confirmed by a correspondent DNA negativity in 8,2% of the samples. This datum should be
investigated further in order to establish if the disease was been eradicated. Patients negative by mRNA
detection in several consecutive follow-ups could be candidates to stop imatinib therapy. The development of
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a DNA base technique could be a powerful tool to evaluate the effective presence/absence of leukemic cells.
Patient 8 resulted negative at 70 months monitored by RNA and DNA technique could be a candidate to stop
the therapy (figure 2).
Conclusion: Although the initial characterization of genomic breakpoint sequence is still time consuming, it
may provide a patient-specific DNA biomarker that can be used to detect the presence of quiescent leukemic
cells otherwise undetectable using a conventional qRT-PCR. The DNA genomic Q-PCR could be a very
sensitive and direct technique to detect minimal residual disease in CML patients treated with tyrosine-
kinase inhibitors and allogeneic transplantation.
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